Last reviewed · How we verify
Vancomycin Injection
Vancomycin Injection, marketed by Murdoch Childrens Research Institute, is a well-established antibiotic in the healthcare sector. The key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. The primary risk lies in the potential increase in competition post-patent expiry, which could impact market share and financial performance.
At a glance
| Generic name | Vancomycin Injection |
|---|---|
| Also known as | Firvanq, vancomycin, placebo, Vancocin, Vancocin Placebo |
| Sponsor | Murdoch Childrens Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease (PHASE2)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia (PHASE4)
- Linezolid or Vancomycin Surgical Site Infection Prophylaxis (PHASE4)
- Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |